Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)

Sponsor:
NCI
Sponsor Study ID:
DCP-001
CTO #:
102483
NCT Number:
Phase:
N/A
Protocol Type:
Other
Age Group:
Adults
Disease Sites:
Anus; Bladder; Bones and Joints; Brain and Nervous System; Breast; Cervix Uteri; Colon; Corpus Uteri; Esophagus; Eye and Orbit; Hodgkin's Lymphoma; Ill-Defined Sites; Kaposi's Sarcoma; Kidney; Larynx; Leukemia, other; Lip, Oral Cavity and Pharynx; Liver; Lung; Lymphoid Leukemia; Melanoma, Skin; Multiple Myeloma; Mycosis Fungoides; Myeloid and Monocytic Leukemia; Non-Hodgkin's Lymphoma; Other Digestive Organ; Other Endocrine System; Other Female Genital; Other Hematopoietic; Other Male Genital; Other Respiratory and Intrathoracic Organs; Other Skin; Other Urinary; Ovary; Pancreas; Prostate; Rectum; Small Intestine; Soft Tissue; Stomach; Thyroid; Unknown Sites
Study Objectives:
1) Implement a screening tool in NCORP to collect broader demographic and clinical data to generate hypothesis and research questions in the following areas of research: cancer screening, cancer prevention, symptom science, cancer care disparities, comparative effectiveness and cancer care delivery research. 2) Collect expanded demographic and clinical data (e.g., SES, co-morbidities, method of diagnosis) across the NCORP network to help identify and best characterize patients that are screened but not enrolled and for patients that participate in NCI trials, to understand how these variables may impact outcomes. 3) Enhance an understanding of site- specific and trial-specific accrual barriers that will inform the development of effective strategies to improve accrual, particularly for minority and underserved populations. 4) Provide data for internal and external evaluation of NCORPs first RFA cycle and reissuance.
eConsent:
Not available
Study Documents:
Open Study Documents
(MUSC NetID required for document access)

For more information about this trial please contact the study team:

Trial opened at the following institutions:

Medical University of South Carolina, Tidelands Health, Ralph H. Johnson VAMC, Self Regional Medical Center, Beaufort Memorial Hospital - SC